Watson announced its launch of Levalbuterol HCl Inhalation Solution, the generic version of Sunovion‘s Xopenex Inhalation Solution.

Xopenex Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children >6 years of age with reversible obstructive airway disease. Levalbuterol is a β2-agonist that relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles.

Levalbuterol HCl Inhalation Solution will be available in 0.31mg/3mL, 0.63mg/3mL, and 1.25mg/3mL dosage strengths. Watson began shipping the product today.

For more information call (800) 272-5525 or visit www.watson.com.